ARCHIVEOBSTETRICS AND GYNECOLOGY
International Medical Journal, Vol. 19., Iss. 4, 2013, P. 38−40.
CLINICAL DIAGNOSTIC VALUE OF ANTIPHOSPHOLIPID ANTIBODIES IN PROGNOSIS OF FETAL GROWTH RETARDATION
City Maternity Hospital No. 5, Kyiv
Complex clinical examination of 130 pregnant with fetal growth retardation syndrome of various degrees of severity and 30 healthy pregnant (controls) was performed to establish clinical diagnostic value of antiphospholipid antibodies in development of fetal growth retardation syndrome. The performed investigation demonstrated that antiphospholipid antibodies concentration over 0.6 U/ml was prognostically unfavorable, associated with increased frequency of severe fetal growth retardation syndrome against a background of prolonged gestosis, marked hemodynamic disorders in the placental complex and low efficacy of the administered therapy. Pregnancy in these women was complicated by placental insufficiency in 100% of cases, severe pre−eclampsia in 70.0% of cases and eclampsia in 2.5% of cases. Considering these data, antiphospholipid antibodies concentration over 0.6 U/ml was determined a threshold in development of severe fetal growth retardation syndrome.
Key words: antiphospholipid antibodies, fetal growth retardation, prognosis.